---

SPECIALTY PHARMACY PRACTICE RESIDENCY IN HEMATOLOGY/ONCOLOGY
Scott and White Clinic and Hospital, Scott, Sherwood and Brindley Foundation, Department of Pharmacy Services
in conjunction with the University of Texas at Austin, College of Pharmacy

LOCATION:
Temple, Texas

LENGTH OF RESIDENCY:
1 year

START DATE:
July 1

REQUIREMENTS:
Pharm.D. degree from ACPE-accredited institution.
Texas licensure by September 1.
A strong interest in oncology pharmacy practice.

STIPEND:
Competitive salary plus an attractive benefits package.

CONTACT:
Jon D. Herrington, Pharm.D., BCPS, BCOP
Department of Pharmacy Services
Scott and White Hospital
2401 South 31st Street
Temple, Texas 76508
(254) 724-4829
jherrington@swmail.sw.org

The Clinical Pharmacy Specialty Residency in Hematology/Oncology offered by Scott & White Hospital is a comprehensive program designed to provide extensive training in hematology/oncology. The purpose of this residency is to provide education and training in conjunction with opportunities to function independently as practitioners by incorporating and building upon accrued experience and knowledge into enhanced patient care. Primary hematology/oncology rotations offered provide an extensive experiential component for hematology/oncology clinical pharmacy practice. Hematology/oncology specific rotations include: oncology, hematology, pain management, pediatric oncology, stem cell transplantation, and ambulatory care. Other rotations are also available: infectious disease, radiation oncology, nutritional support, managed care, pharmacy administration, surgery, and many additional electives are available. The residency experience is highly individualized; rotations are chosen and designed according to needs and interests of the resident.

The resident participates in multidisciplinary educational activities, including presentation of lectures and inservices, supervision of pharmacy students on clinical rotations, informal teaching of medical students and residents, and teaching of pharmacists and nurses. Opportunities are available to participate in ongoing research and to publish in peer-reviewed journals.

Previous residents have published articles, chapters, and presented projects at meetings during their residency periods.

• #Brown EN, Herrington JD. Review of the relationship between venous thromboembolism, malignancy and its treatment.  J Pharm Practice 2008;21:126-37.


• #Brown EN, Herrington JD, Song J, Atkinson S. Evaluation of Venous Thromboembolism Recurrence in Cancer Patients Receiving Anticoagulation Therapy: Anticoagulation Clinic Using Warfarin versus Oncology Clinical Practice Using LMWH.  42nd Annual American Society of Health-System Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 5, 2007.

• *Ziegler JA, Herrington JD.  Current and future options for the treatment of chemotherapy-induced anaemia. Expert Opin Investig Drugs 2006;15:1051-65.


• *Ziegler JA, Herrington JD. Retrospective evaluation of antiemetic utilization in pediatric oncology patients undergoing chemotherapy.  40th Annual American Society of Health-System Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 8, 2005.

• Herrington JD, †Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.  Cancer 2008;112:2080-7.

• †Jaskiewicz AD, Herrington JD, Wong L. Tumor lysis syndrome following bortezomib (Velcade) treatment in plasma cell leukemia. Pharmacotherapy 2005;25:1820-25.

• †Jaskiewicz AD, Martin III ES, Herrington JD. Failure mode and effect analysis (FMEA) of the chemotherapy medication process at Scott and White Memorial Hospital and Clinics. 39th Annual American Society of Health-System Pharmacists Midyear Clinical Meeting. Orlando, FL, December 8, 2004.


• Herrington JD, #Labdi BL. Nausea, vomiting and anorexia. In: Tisdale JE, Miller DA, eds. Drug-induced Diseases: Prevention, Detection, and Management, 1st ed. Bethesda, MD: American Society of Health-System Pharmacists. 2005;555-79.

• #Labdi BA, Herrington JD. Evaluation of infectious complications of CVCs in Scott & White Oncology Patients. 38th Annual American Society of Health-System Pharmacists Midyear Clinical Meeting, New Orleans, LA, December 11, 2003.


• #Cool RM, Herrington JD, Wong L. Recurrent peripheral arterial thrombosis from cisplatin and etoposide. Pharmacotherapy 2002;22:1200-4.

• #Cool RM, Herrington JD.  Thalidomide in the management of relapsed and recurrent multiple myeloma.  Pharmacotherapy 2002;22:1019-28. 


• #Cool RM, Herrington JD, Wong L. Arterial Thrombosis after Chemotherapy with Cisplatin and Etoposide. 36th Annual American Society of Health-System Pharmacists Midyear Clinical Meeting, New Orleans, LA, December 4, 2001.

* Currently employed as decentralized oncology pharmacist at Wake Forest University Baptist Medical Center, Winston-Salem, NC
# Currently employed as pharmacy clinical specialists at the University of Texas, MD Anderson Cancer Center, Houston, TX
† Currently employed as Oncology Regional Medical Liaison, Amgen, Inc.
Clinical Specialty Residents at Scott and White are offered an appointment as Clinical Instructor, College of Pharmacy, The University of Texas at Austin. This affiliation conveys additional educational opportunities as well as fringe benefits.

Pharmacy professionals at Scott and White include specialty clinical practitioners in adult medicine, hematology/oncology, infectious disease, pediatrics, ambulatory care, managed care, pharmacoeconomics, and drug information and patient care pharmacists in a variety of patient areas. Comprehensive, progressive pharmacy services are provided to both inpatients and outpatients. The clinical pharmacy specialists are faculty members of Texas A&M University Health Science Center and The University of Texas College of Pharmacy.

Also provided are free copying services, professional assistance with presentation preparation, and paid expenses for attendance at one national and one regional meeting during the year.

Outstanding opportunities exist for Pharm.D. students and residents to develop clinical practice, teaching and research skills in this health care environment where a commitment to patient care, education, and research exists.

The University of Texas at Austin and its affiliated institutions are an Equal Opportunity/Affirmative Action Employer.  Qualified women and minorities are encouraged to apply.  Security sensitive; conviction verification conducted on applicant selected.